11/9/2004
2004 Third Quarter Earnings

Three months Ended September 30
Nine Months Ended September 30
2004
2003
2004
2003
Total Revenue
$1,119,549
$904,183
$3,183,314
$2,413,467
Net Income (loss)

$(58,968)

$(180,041)
$(300,665)
$(702,280)
Weighted Average Number of Shares Outstanding
4,610,493
4,645,826
4,619,048
4,646,347
Equivalent Share
$(0.01)
$(0.04)
$(0.06)
$(0.15)

New York, NY, November 9, 2004 - The Company has continued to expand its sales and marketing team for the blood volume analyzer. As of October 31, 2004 kit sales were increased 31% as compared to the comparable 10 months of 2003.

In addition to its sales staff, in the past 4 months the Company has instituted a program of hiring account representatives, whose primary function is to assist institutions in educating their physicians to better understand the benefits of the blood volume analyzer for their patients.

In the past year, there were 3 important papers published on research performed at Columbia Presbyterian Medical Center in New York on the benefits of obtaining a normal blood volume in congestive heart failure patients. The Company anticipates the publication of additional papers in peer review journals about the benefits and accuracy of the blood volume analyzer in the treatment of medical and surgical conditions.

 
 
For more infomation, please contact:
Rich Dunn
Director of Operations
212-330-8502
Diane Meegan
Investor Relations
212-330-8512